Completion of Rights Offer and Cleansing Notice

RIGHTS OFFER COMPONENT OF PACIFIC EDGE'S $21.3 MILLION OFFER COMPLETED Pacific Edge Limited (Pacific Edge) is pleased to advise it has completed the Rights Offer component of its underwritten 1 for 6 rights offer (Offer) of new ordinary shares in Pacific Edge (New Shares), which closed on 8 November 2017. Approximately 48.5 million New Shares, at a price of NZ$0.32 per New Share, were taken up under the Rights Offer. This represents approximately 72.9% of the New Shares available under the Rights Offer. In addition, applications totalling approximately NZ$1.47 million have been received from Eligible Shareholders in respect of the Shortfall Bookbuild portion of the Offer (described below). The New Shares taken up by Eligible Shareholders under the Offer are expected to be issued and commence trading on the NZX Main Board on Wednesday 15 November 2017 and will rank equally with existing ordinary shares of Pacific Edge (Shares). SHORTFALL BOOKBUILD Approximately 18.1 million New Shares are available in the shortfall bookbuild component of the Offer (Shortfall Bookbuild), which will be conducted tomorrow, Friday 10 November 2017. The additional applications received from Eligible Shareholders will form part of the Shortfall Bookbuild on the terms set out in the Offer Document. Shareholders who did not take up their full entitlements under the Rights Offer or were ineligible to do so will receive a share of any Premium achieved (being the amount by which the Bookbuild Price exceeds the Issue Price for the New Shares of NZ$0.32 per New Share) in proportion to the Rights which they did not take up. There is no guarantee that the Shortfall Bookbuild will result in a Premium. Further Information Shareholders who have any questions about the Rights Offer or the Shortfall Bookbuild are encouraged to read the Offer Document on the NZX website, www.nzx.com/companies/PEB, and seek financial, investment, or other professional advice from a qualified professional adviser. Pacific Edge will apply for its Shares to be placed in trading halt on NZX on Friday 10 November 2017 and remain in trading halt until an announcement containing the results of the Shortfall Bookbuild is made, which is expected to occur on Monday 13 November 2017. - ENDS - David Darling Chief Executive Officer Pacific Edge Ltd Cell: +64 21 797 981 Ph: +64 3 4795 800 Note: All capitalised terms used in this announcement have the meanings given to them in the Offer Document dated 18 October 2017. This announcement has been prepared for publication in New Zealand and may not be released or distributed in the United States. This announcement does not constitute an offer to sell, or a solicitation of an offer to buy securities in the United States or any other jurisdiction. Any securities described in this announcement have not been, and will not be, registered under the US Securities Act of 1933 and may not be offered or sold in the United States, except in transactions exempt from, or not subject to, the registration of the US Securities Act and applicable US state securities laws. OVERVIEW www.pacificedge.co.nz www.pacificedgedx.com Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer diagnostic company specialising in the discovery and commercialisation of diagnostic and prognostic tests for better detection and management of cancer. The company is developing and commercialising its range of Cxbladder bladder cancer tests globally through its wholly owned central laboratories in New Zealand and the USA. The company's products have been tested and validated in international multi-centre clinical studies. Pacific Edge has three proprietary, novel, accurate, molecular diagnostic products in-market providing actionable results, and better detection and management of urothelial cancer. Cxbladder Detect and Cxbladder Triage are available through the company's dedicated CLIA certified laboratories for customers in New Zealand, Australia and the USA. Cxbladder Monitor launched in New Zealand in December 2015 and is anticipated being available in the US in 2016. ABOUT Cxbladder Triage www.cxbladder.com Cxbladder Triage combines the power of the genomic biomarkers with additional phenotypic and clinical risk factors to accurately identify patients with haematuria who have a low probability of bladder cancer and may not require a more extensive urological evaluation. Cxbladder Triage is a tool for use by clinicians and physicians in primary evaluation of patients with haematuria and is intended to reduce the need for an expensive and invasive work-up in patients who have a low probability of having urothelial carcinoma. ABOUT Cxbladder Detect www.cxbladder.com Cxbladder Detect enables the non-invasive detection of bladder and other urinary tract cancers from a small volume of a patients' urine. Cxbladder Detect was launched in 2013 in the USA and is commercially available in New Zealand, Australia and the USA as a Laboratory Developed Test (LDT) from the company's CLIA certified laboratories. Cxbladder Detect provides clinicians with a quick, cost effective and accurate measure of the presence of the cancer as an effective adjunct to cystoscopy. ABOUT Cxbladder Monitor www.cxbladder.com Cxbladder Monitor, the third test in the Cxbladder portfolio for urologists, is a proprietary, non-invasive, molecular diagnostic test that combines genomic biomarkers measured from a small quantity of a patient's urine, with patient specific clinical factors to better monitor bladder cancer patients for recurrence. Bladder cancer has a recurrence rate of 50-80% and requires life-long surveillance. Cxbladder Monitor accurately identifies patients with a prior history of urothelial cancer (UC) whose Cxbladder Monitor score shows that they have a low probability of recurrent urothelial carcinoma. Cxbladder Monitor is designed to be used as the preferred adjunct test to cystoscopy in the management of patients for ongoing evaluation of recurrent bladder cancer. ABOUT Cxbladder Resolve www.cxbladder.com Cxbladder Resolve is a proprietary, non-invasive, molecular diagnostic test that combines genomic biomarkers measured from a small quantity of a patient's urine, with patient characteristics for the identification of patients who are likely to have aggressive or more advanced bladder cancer. Cxbladder Resolve, when used as part of the primary evaluation of haematuria and/or in conjunction with other Cxbladder tests (Triage, Detect), is designed to assist clinicians by accurately identifying patients with a high probability of having high grade or late stage bladder cancer, for whom alternative or expedited treatment options may be warranted, or who can be prioritised for further investigation in high throughput settings. Refer to www.cxbladder.com for more information. End CA:00310078 For:PEB Type:OFFER Time:2017-11-09 16:55:37